The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

Shelankova A.V.

Research Institute of Eye Diseases

Andreeva Yu.S.

Research Institute of Eye Diseases

Prevention of intraocular pressure elevation following intravitreal injections

Authors:

Budzinskaya M.V., Shelankova A.V., Andreeva Yu.S.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(5‑2): 240‑246

DOI: 10.17116/oftalma2022138052240

Read: 2382 times

Download PDF (RU)
Contact the author
Table of contents

PREVENTION OF INTRAOCULAR PRESSURE ELEVATION FOLLOWING INTRAVITREAL INJECTIONS
PREVENTION OF INTRAOCULAR PRESSURE ELEVATION FOLLOWING INTRAVITREAL INJECTIONS

To cite this article:

Budzinskaya MV, Shelankova AV, Andreeva YuS. Prevention of intraocular pressure elevation following intravitreal injections. Russian Annals of Ophthalmology. 2022;138(5‑2):240‑246. (In Russ.)
https://doi.org/10.17116/oftalma2022138052240

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Long-term outcomes of phakic intraocular lens implantation in high myopia. Russian Annals of Ophthalmology. 2025;(1):28-31
Proton pump inhi­bitors: posi­tive and nega­tive properties. On the 45th anni­versary of their discovery. Russian Journal of Preventive Medi­cine. 2024;(11):135-140
Study of opinions of medi­cal students on medi­cal prevention issues. Russian Journal of Preventive Medi­cine. 2024;(12):69-74
Asse­ssment of risk of deve­loping fractures and sarcopenia and quality of life of patients with chro­nic kidney disease at the outpatient stage. Russian Journal of Preventive Medi­cine. 2024;(12):88-91
Gastric cancer: inci­dence, risk factors, screening. Russian Journal of Preventive Medi­cine. 2024;(12):135-139
The rela­tionship of diet and nutrition with the frequency of migraine atta­cks. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):30-35
Prevention of periodontal inflammation in microgravity mode­ling. Stomatology. 2024;(6-2):23-28
Effe­ctiveness of risk-guided cardiac mana­gement in patients with HER2-positive breast cancer and cancer therapy-related cardiac dysfunction. Russian Cardiology Bulletin. 2024;(4-2):144-153
Obstructive sleep apnea syndrome as a predictor of atrial fibrillation. Russian Journal of Preventive Medi­cine. 2025;(1):109-114
Vita­min D role in oral cavity diseases. Stomatology. 2025;(1):81-86
Abstract:

Determining the role of vascular endothelial growth factor (VEGF) in the pathogenesis of intraocular neovascularization prompted the development of anti-VEGF therapy. In general, these intravitreal injections (IVI) are considered relatively safe. One of the side effects that can occur after IVI of anti-VEGF agents is ocular hypertension, it can be acute or persistent. Numerous studies investigating the prevention of ophthalmic hypertension have been carried out in connection with the proven risk of short-term intraocular pressure (IOP) elevation after anti-VEGF injections. Scientific literature describes several methods of preventing intraocular pressure spikes after IVI: prophylactic medications, anterior chamber paracentesis, scleral decompression. Despite the significant number of publications, there is no universal consensus on the necessity of prevention measures for IVI of anti-VEGF drugs since the clinical benefits of slightly reducing the short-term IOP spikes remain unclear. This literature review analyzes the prospects of preventing ocular hypertension after IVI of anti-VEGF agents.

Keywords:

anti-VEGF drugs
intravitreal injection
intraocular pressure
prevention

Authors:

Budzinskaya M.V.

Krasnov Research Institute of Eye Diseases

Shelankova A.V.

Research Institute of Eye Diseases

Andreeva Yu.S.

Research Institute of Eye Diseases

Received:

07.12.2021

Accepted:

24.03.2022

Close metadata

References:

  1. Ohm DJ. Über die Behandlung der Netzhautablösung durch operative Entleerung der subretinalen Flüssigkeit und Einspritzungvon Luft in den Glaskörper [About the treatment of retinal detachment by surgical emptying of the subretinal fluid and injectionof air into the vitreous body]. Albrecht von Graefes Archiv für Ophthalmologie. 1911;79:442-450.  https://doi.org/10.1007/BF01977971
  2. Sorsby A, Ungar J. The control of experimental infections of the anterior chamber and of the vitreous by subconjunctival and retrobulbar injections of crystalline penicillin in doses of 1,000,000 units. The British Journal of Ophthalmology. 1948;32(12):873-878.  https://doi.org/10.1136/bjo.32.12.873
  3. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. The New England Journal of Medicine. 2004;351(27):2805-2816. https://doi.org/10.1056/nejmoa042760
  4. Karpilova MA, Durzhinskaya MH. Anti-VEGF drugs in the treatment of neovascular glaucoma. Vestnik oftal’mologii. 2019;135(5):299-304. (In Russ.). https://doi.org/10.17116/oftalma2019135052299
  5. Sakalova ED, Avetisov KS, Budzinskaya MV, Andreeva IV. Pathogenesis and diagnosis of postoperative macular edema. Vestnik oftal’mologii. 2017;134(41): 107-112. (In Russ.). https://doi.org/10.17116/oftalma20181341107-112
  6. Budzinskaia MV, Pliukhova AA, Toropygin SG. Modern view on the treatment of wet-AMD patients. Vestnik oftal’mologii. 2019;135(5):107-115. (In Russ.). https://doi.org/10.17116/oftalma2019135051107
  7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2006; 355(14):1419-1431. https://doi.org/10.1056/NEJMoa054481
  8. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. The Cochrane Database of Systematic Reviews. 2019;3(3):CD005139. https://doi.org/10.1002/14651858.CD005139.pub4
  9. Budzinskaya MV, Plyukhova AA. Future Perspectives for Antiangiogenic Therapy in Retinal Diseases. Oftal’mologiya. 2021;18(3S):638-645. (In Russ.). https://doi.org/10.18008/1816-5095-2021-3S-638-645
  10. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. The New England Journal of Medicine. 2011; 364(20):1897-1908. https://doi.org/10.1056/nejmoa1102673
  11. Sampat KM, Garg SJ. Complications of intravitreal injections. Current Opinion in Ophthalmology. 2010;21(3):178-183.  https://doi.org/10.1097/icu.0b013e328338679a
  12. Budzinskaia MV, Strakhovskaya MG, Andreeva IV, Khalatyan AS. Conjunctival microflora and its antibiotic sensitivity after serial intravitreal injections. Vestnik oftal’mologii. 2019;135(5):135-140. (In Russ.). https://doi.org/10.17116/oftalma2019135052135
  13. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. American Journal of Ophthalmology. 2008;146(6):930-934.e1.  https://doi.org/10.1016/j.ajo.2008.07.007
  14. Ermolaev AP, Pershin BS, Surguch VK, Mustyaca VF. Impact of intravitreous injection of additional volume of liquid on intraocular pressure. Vestnik Rossijskogo universiteta druzhby narodov. Seriya: Medicina. 2010;3:64-67. (In Russ.).
  15. Bubnova IA, Kurguzova AG. Changes in intraocular pressure after intravitreal injections. Vestnik oftal’mologii. 2018;134(4):47-51. (In Russ.). https://doi.org/10.17116/oftalma201813404147
  16. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. The British Journal of Ophthalmology. 2011;95(8):1111-1114. https://doi.org/10.1136/bjo.2010.180729
  17. Kahook MY, Liu L, Ruzycki P, Mandava N, Carpenter JF, Petrash JM, Ammar DA. High molecular weight aggregates in repackaged bevacizumab. Retina. 2010;30(6):887-892.  https://doi.org/10.1097/iae.0b013e3181d50cea
  18. Pece A, Allegrini D, Montesano G, Dimastrogiovanni AF. Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study. Clinical Ophthalmology. 2016;10: 1131-1138. https://doi.org/10.2147/opth.s106096
  19. Song S, Yu X, Dai H. Effect of prophylactic intraocular pressure-lowering medication (brinzolamide) on intraocular pressure after ranibizumab intravitreal injection: A case-control study. Indian Journal of Ophthalmology. 2016;64(10):762-766.  https://doi.org/10.4103/0301-4738.195006
  20. Ozcaliskan S, Ozturk F, Yilmazbas P, Beyazyildiz O. Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection. International Journal of Ophthalmology. 2015;8(3):496-500.  https://doi.org/10.4274/tjo.26122
  21. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klinische Monatsblatter fur Augenheilkunde. 2010;227(4): 280-284.  https://doi.org/10.1055/s-0029-1245201
  22. El Chehab H, Le Corre A, Agard E, Ract-Madoux G, Coste O, Dot C. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. European Journal of Ophthalmology. 2013;23(3):277-283.  https://doi.org/10.5301/ejo.5000159
  23. Dettoraki M, Rapti E, Fragkos D, Theiopoulos I, Legaki A, Gkounta A, Anyfantaki D, Riga F. Prophylactic effect of brinzolamide—brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections. International Ophthalmology. 2021;41(9):3191-3198. https://doi.org/10.1007/s10792-021-01885-z
  24. Murray CD, Wood D, Allgar V, Walters G, Gale RP. Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye. 2014;28(10):1218-1222. https://doi.org/10.1038/eye.2014.180
  25. Katayama BY, Bonini-Filho MA, Messias AM, Paula JS, Martin LF, Costa R, Jorge R. Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. Journal of Glaucoma. 2014; 23(7):461-463.  https://doi.org/10.1097/ijg.0b013e3182948476
  26. Frenkel MPC, Haji SA, Frenkel REP. Effect of Prophylactic Intraocular Pressure—Lowering Medication on Intraocular Pressure Spikes after Intravitreal Injections. Archives of Ophthalmology. 2010;128(12):1523-1527. https://doi.org/10.1001/archophthalmol.2010.297
  27. Shoeibi N, Ghosi Z, Jafari H, Omidtabrizi A. Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections. International Ophthalmology. 2021;41(3):1081-1090. https://doi.org/10.1007/s10792-020-01667-z
  28. Eakins KE, Whitelocke RAF, Bennett A, Martenet AC. Prostaglandin-like activity in ocular inflammation. British Medical Journal. 1972;3(5824): 452-453.  https://doi.org/10.1136/bmj.3.5824.452
  29. Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F, Reche-Frutos J, Calvo-Gonzalez C, Donate-Lopez J, Garcia-Feijoo J. Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Investigative Ophthalmology and Visual Science. 2012;53(10):6214-6218. https://doi.org/10.1167/iovs.12-9875
  30. Bubnova IA, Yulova AG. Optic nerve head changes with acute IOP elevation after intravitreal injections. Nacional’nyj zhurnal Glaukoma. 2016;15(2):54-60. (In Russ.).
  31. Bracha P, Moore NA, Ciulla TA, Cantor LB. The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A Review. Survey of Ophthalmology. 2018;63(3):281-295.  https://doi.org/10.1016/j.survophthal.2017.08.008
  32. Knip MM, Valimaki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmologica. 2012;90(3):254-258.  https://doi.org/10.1111/j.1755-3768.2010.01904.x
  33. Trivedi D, Denniston AK, Murray PI. Safety profile of anterior chamber paracentesis performed at the slit lamp. Clinical and Experimental Ophthalmology. 2011;39(8):725-728.  https://doi.org/10.1111/j.1442-9071.2011.02565.x
  34. Soheilian M, Karimi S, Montahae T, Nikkhah H, Mosavi SA. Effects of intravitreal injection of bevacizumab with or without anterior chamber paracentesis on intraocular pressure and peripapillary retinal nerve fiber layer thickness: a prospective study. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2017;255(9):1705-1712. https://doi.org/10.1007/s00417-017-3702-1
  35. Morlet N, Young S. Prevention of intraocular pressure rise following intravitreal injection. The British Journal of Ophthalmology. 1993;77(9):572-573.  https://doi.org/10.1136/bjo.77.9.572
  36. Nuzzi R, Scalabrin S, Becco A. Reduction of Intraocular Pressure Spikes Due to Intravitreal Bevacizumab Injections by Scleral Indentation with Cotton Swab or Digital Ocular Massage: Innovative Techniques Compared. Clinical Ophthalmology. 2020;14:2533-2541. https://doi.org/10.2147/OPTH.S263474
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.